The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.

Saved in:
Bibliographic Details
Title: The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
Authors: Stringer F; Takeda Pharmaceutical Company, 1-1, Doshomachi 4-Chome, Chuo-Ku, Osaka 540-8645, Japan. fran.stringer@takeda.com, Scott G, Valbuena M, Kinley J, Nishihara M, Urquhart R
Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2013 Mar; Vol. 69 (3), pp. 423-30. Date of Electronic Publication: 2012 Sep 09.
Publication Type: Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1432-1041
DOI:10.1007/s00228-012-1382-7